What is TB-500 used for?
TB-500 is used in preclinical research across dermal wound-healing, cardiac-repair, corneal-epithelial-repair, limb-ischemia revascularisation, hair-follicle biology, kidney-injury, and inflammatory-disease research contexts. The compound is the synthetic acetylated fragment of thymosin β4 used as a tractable research-supply form.
What the research literature says
TB-500’s research applications cluster around the cytoskeletal-remodelling and integrin-linked kinase pharmacology that derives from the parent thymosin β4 protein. The published research literature spans cardiac repair (Bock-Marquette work documenting integrin-linked kinase activation and cardiac-cell migration, PMID 15565145; Dubé cardiac-repair review, PMID 22236126), dermal healing (Kleinman review, PMID 27450738), corneal repair (Sosne corneal wound-healing work, PMID 11950239), and limb-ischemia angiogenesis (Lv Notch/NF-κB pathway work, PMID 32945357).
The actin-binding pharmacology characterised by the Yarmola ternary-complex work (PMID 11579089) is the structural mechanism that underlies the broad cell-type applicability. G-actin sequestration is operative in any cell type undergoing cytoskeletal remodelling, which explains why TB-500’s published research spans tissue-repair contexts as diverse as cardiac, dermal, corneal, vascular, and kidney research.
The integrin-linked kinase arm characterised by Bock-Marquette extends the mechanism beyond actin-binding into receptor-mediated downstream signalling on cardiac and endothelial cells. Both arms operate independently and contribute distinct components to the integrated TB-500 pharmacology.
Why this matters in research context
TB-500’s research applications are broader than the BPC-157 portfolio because the actin-binding pharmacology applies across more cell types. Researchers selecting TB-500 should anchor protocol design to the specific tissue-repair or cell-migration context most relevant to the experimental question. The Wolverine Stack combination format pairs TB-500 with BPC-157 for combined-research protocols where both mechanism arms are research-relevant.
Related compounds
- TB-500 10mg — the compound covered by this answer
- Wolverine Stack (BPC-157 + TB-500 blend) — combined-formulation for tissue-repair research
Related research questions
- What is the half-life of TB-500?
- How do BPC-157 and TB-500 differ?
- Is TB-500 the same as thymosin beta 4?
References
- Yarmola EG et al. Formation and implications of a ternary complex of profilin, thymosin beta 4, and actin. J Biol Chem 2001;276(49):46094-46101. [PMID 11579089]
- Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-472. [PMID 15565145]
- Kleinman HK et al. Thymosin β4 Promotes Dermal Healing. Vitam Horm 2016;102:251-275. [PMID 27450738]
- Lv S et al. Thymosin-β 4 induces angiogenesis in critical limb ischemia mice via regulating Notch/NF-κB pathway. Int J Mol Med 2020;46(4):1347-1358. [PMID 32945357]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. TB-500 is sold strictly as a research-grade reagent for laboratory and bench research applications.